neurodegenerative disorders. Beside the classical neuropathological triad (spongiform change, astrogliosis, and neuronal loss), PrD are characterized by the accumulation of an abnormal isoform of the host-encoded prion protein (PrP). 1 In human PrD, this affects nervous tissue in sporadic Creutzfeldt-Jakob disease (sCJD) 2 as well as in lymphoid tissue in bovine spongiform encephalopathy-linked variant Creutzfeldt-Jakob disease (vCJD). 3, 4 Tissue-related diagnosis of PrD can be achieved by post-mortem examination of the brain 2 and also by detection of disease-associated prion protein (PrP Sc ) in lymphoid tissue biopsy in vCJD. 4 Detection of PrP Sc in blood samples as a specific diagnosis for PrD would require its transport across vessel walls. As PrP Sc is postulated as the infectious particle in PrD, 1 this transport can also be interpreted as spread of infectivity. Blood transfusion is not considered to carry a risk in sporadic cases, 5 although it may transmit disease in acquired PrD. 6 To evaluate this pathway we examined intracranial and extracranial vessels in different PrD subtypes, and we demonstrate the presence of PrP Sc in vessel walls.
Materials and Methods

Case Selection
Formalin-fixed, paraffin-embedded tissue blocks from the cerebral cortex, basal ganglia, thalamus, brain stem, cerebellum and/or basal arteries (eg, basilar artery and/or branches of circulus Willisi) were obtained from 30 sCJD, 17 vCJD, 4 iatrogenic (growth hormone application) CJD (iCJD), and 30 unselected control cases with a variety of neuropathological diagnoses including brain tumors, inflammatory, neurodegenerative, and cerebrovascular diseases. In three sCJD, two vCJD, and two controls we inves-tigated extracranial segments of carotid artery and/or ascending aorta as well.
Immunocytochemistry
For detection of PrP
Sc
, we stained sections with 3F4 (monoclonal, 1:500, Senetek PLC, Napa, CA, USA) after a threetiered tissue pretreatment, including 10 minutes of hydrated autoclaving at 121°C, 5 minutes of 96% formic acid, and 2 hours of 4 mol/L guanidine thiocyanate at 4°C. In cases with immunoreactivity (IR) in the vessel wall, we then obtained adjacent sections and used antibodies 6H4 (monoclonal, 1:500, Prionics, Zurich, Switzerland) and 12F10 (monoclonal, 1:1000, CEA, Fontenay-aux-Roses, France). To characterize labeled cells, we performed immunostaining for HLA-DR (CR3/43, monoclonal, 1:100, DAKO, Glostrup, Denmark), CD 68 (KP1, monoclonal, 1:100, DAKO), and S100 (polyclonal, 1:2000, DAKO). As a secondary system, we used the ChemMate detection kit (DAKO). Negative controls included omission or substitution of primary antibodies by nonspecific, isotype-matched antibodies. 
Double Immunofluorescence
Paraffin-Embedded Tissue Blot
Paraffin-embedded tissue (PET) blot was performed on basal intracranial arteries from one sCJD and extracranial carotid and aorta from one vCJD case. Paraffin-embedded tissue sections were placed onto nitro-cellulose 
membrane for detection of PrP
Sc using the antibody 3F4 (monoclonal, 1:500, DAKO, Denmark) after proteinase K digestion. Labeling was carried out following the protocol of Schulz-Schaeffer et al, 7 with the alkaline phosphatasecoupled rabbit anti-mouse antibody replaced by an avidin-biotin system. A negative control, in which the primary antibody was omitted, was included for each section examined. Labeling was observed using a stereoscopic microscope.
Results
Using specific pretreatment and an immunostaining procedure for PrP Sc , 8 we observe focal granular PrP IR in intracranial vessel walls of 6 of 30 sCJD, 3 of 17 vCJD, and none of the iCJD and control cases. It locates predominantly to the media of deep perforating and occasionally of meningeal and basal arteries (Figure 1a ) as well as of small parenchymal vessels. Rarely do we observe it in the intima. We do not observe a correlation between PrP deposits in the brain parenchyma (eg, diffuse/synaptic, plaque) and presence of vessel wall PrP IR. In cases where we find PrP deposits in the vessel wall, it can be seen most often in more than one vessel and in different brain regions, whereas in other cases (iCJD), serial sections covering about 100 m did not reveal PrP vessel wall deposits. In addition, perivascular PrP deposits are not only predominant in vCJD (Figure 1b) and iCJD, but also in sCJD cases. Nevertheless, as we rarely found more extensive PrP aggregates throughout the vessel wall (Figure 1c ), we excluded their amyloid nature by the absence of congophilia and birefringence.
In extracranial carotid (Figure 1d ) and ascending aorta we observe fine granular PrP IR in 2 of 2 vCJD, 0 of 3 of sCJD cases, and 0 of 2 controls. This is rather widespread and predominates in the outer part of the media and less in the intima and inner part of the media.
Using the PET blot, small, intense areas of PrP positivity are also observed within the intracranial vessels in one case of sCJD, selected from the six immunocytochemically positive sCJD cases. In many of the vessels, these intense clustered deposits appear to follow a linear pattern of labeling (Figure 2 ). Extracranial carotid and aorta vessels in one vCJD case, selected from the two immunocytochemically positive vCJD cases, were found to be negative for PrP using the PET blot.
In adjacent sections of intracranial vessels and in double-immunofluorescent labeling, PrP deposits, in part, co-localize in the perivascular area and in the media of vessels with CD68 IR (Figure 1b) and HLA-DR IR ( Figure  1f and Figure 3 ,a-d) cells, and in the intima with HLA-DR IR and CD68 IR (Figure 1e and Figure 3 , e-h) or S-100 IR cells (Figure 3, i-l) .
Discussion
Here we demonstrate the presence of PrP IR in vessel walls. We think that this represents predominantly PrP Sc . We did not see similar IR in control cases, moreover, isotype antibody controls were negative. All three applied monoclonal anti-PrP antibodies, including 6H4 and 12F10 that we recently showed to be most reliable for PrP Sc detection, 8 immunostained these deposits. Furthermore, PET blot studies fully support the immunocytochemical findings in the intracranial vessels, and confirm that protease-resistant PrP is present within the wall of the vessels in a focal distribution, consistent with the localization also demonstrated by double-immunofluorescence labeling. This type of PrP IR in vessel walls must be differentiated from that seen in stop mutation at codon 145 of the PRNP 9 since the presently described form lacks amyloid features.
The PET blot studies on two extracranial vessels of one vCJD case were unable to demonstrate protease-resistant PrP. The immunocytochemical findings in these vessels are therefore of uncertain significance at present. Possible explanations include up-regulation of the normal cellular isoform of the protein, or a conformational transition of PrP which is protease-sensitive but disease-associated, as has been recently described using conformation-dependent immunoassay in hamsters inoculated with different scrapie strains. 10 However, the most likely explanation might be that the very fine granular PrP deposits seen by immunocytochemistry are not visible in a "gross" method such as a PET blot. Further studies (including Western blot analysis and experimental transmission) are required to investigate these intriguing possibilities.
We did not detect any vessel wall PrP IR in the four iCJD cases. On one hand we examined only few cases, but, on the other hand, we performed serial sectioning covering about 100 m without any result. In any case, we cannot exclude the possibility of missing focal PrP deposits in these vessels. The reason for not detecting PrP-IR in iCJD, if confirmed, remains obscure at present.
Intracranial vessel wall PrP deposits may represent PrP
Sc derived from the periarterial interstitial fluid, which joins the cerebrospinal fluid that may harbor PrP Sc11,12 in some, but not all, CJD cases. 13 Our results resemble the findings in Alzheimer's disease, where ␤-amyloid deposits are seen in intracranial but not in extracranial arteries. It is suggested that ␤-amyloid, often located perivascularly, follows interstitial fluid drainage along the periarterial space of intracerebral, leptomeningeal arteries, and intracranial carotid to join deep cervical lymph nodes. 14 The MHC class II antigen HLA-DR is expressed on numerous immunocompetent cells in the vasculature, including dendritic cells and macrophages. 15 We identified one PrP
Sc -associated cell type in the vessel wall and perivascular area as CD68-positive macrophages, which an arrow) with HLA-DR in the media of a leptomeningeal artery in sporadic Creutzfeldt-Jakob disease (sCJD) (3F4/HLA-DR double immunofluorescence; magnification, ϫ600; green color represents PrP, red HLA-DR represents immunopositivity, blue color indicates the nuclei; Int, intima; Med, media of vessel wall). All colors are combined in d. In the lumen of the artery red blood cells and between intima and media, the internal elastic layer shows autofluorescence. e-h: PrP co-localization (indicated by an arrow) with CD68 in the intima of a basal artery in sCJD (3F4/CD68 double immunofluorescence; magnification, ϫ1000; green color represents PrP, red CD68 indicates immunopositivity, blue color indicates the nuclei; Int, intima; Med, media of vessel wall). All colors are combined in h. i-l: PrP co-localization with S-100 in the intima of a basal artery in sCJD (3F4/CD68 double immunofluorescence; magnification, ϫ600; green color represents PrP, red S-100 represents immunopositivity, blue color indicates the nuclei; Int, intima; Med, media of vessel wall). All colors are combined in l. Between intima and media, the internal elastic layer (i and l) shows autofluorescence.
have a scavenger role in the central nervous system. 16, 17 Macrophages are important in scrapie pathogenesis. They may take up PrP Sc , sequester scrapie infectivity, and impair early scrapie agent replication, 18 -20 or might be vehicles for exporting PrP Sc from the brain to the periphery.
In a recent study, occasional perivascular macrophages surrounding cortical capillaries were PrP-immunoreactive in some non-PrD cases, 21 proposing that they express PrP C . The abundant aggregated PrP deposits in the perivascular area (Figure 1b) , some of which were related to CD68 IR cells, can be distinguished from these, as they represent disease-associated PrP deposits that are absent in non-PrD cases. Perivascular macrophages of the brain have a high rate of turnover by bone marrowderived blood cells 22, 23 and might represent a pathway for neuroinvasion of vCJD that is alternatively spread along peripheral nerves. 24 In addition to neural tissue, S-100 is expressed in vascular-associated dendritic cells (VADC). 25 Dendritic cells are potentially mobile, antigen processing, and presenting cells with endophagocytic and lysosomal activity, 26 and thus are ideal candidates for transport of the infectious agent. VADCs, a network of which is known to be present in arterial vessels of healthy individuals 25 are also related to atherosclerotic lesions with a possible role of T-cell activation. 27 Dendritic cells can migrate via the blood to the spleen or via lymph into lymph nodes where they are known as interdigitating cells. Close contact between VADCs and macrophages suggest a possible interaction between these cell types processing immunological information. VADCs may also migrate across vessel walls (to eg, lymphoid tissue). Thus, they might serve as common link between pathogenic events in the periphery as well as in neuroinvasion of prion diseases. 28 We widen the spectrum of tissues which contain PrP Sc . Immunocompetent cells of vessel walls may participate in PrP Sc production (analogously to follicular dendritic cells) and/or transport. As these cells might be in contact with both neural and extraneural tissue, our results raise the possibility of mobile cell-related spread of PrP Sc and infectivity. Early detection of abnormal PrP in lymphoreticular tissues of gastrointestinal tract in mice after intracerebral inoculation of the CJD agent supports this theory. 29 -31 In addition to established extraneural tissue infectivity in vCJD, 32 the occasional infectivity of extraneural tissues of sCJD patients 12 might result from this kind of PrP Sc transport. Furthermore, our results suggest that PrP
Sc may be present in the blood, albeit in sCJD probably at very low levels. Moreover, this encourages the rationale for blood-based prion diagnostics using sensitive detection methods like protein misfolding cyclic amplification. 33 
